mRNA melanoma vaccine cuts recurrence risk over 40 percent

What BBN said about it

1. 

   Hank Ledger · Lead AnchorA personalized mRNA vaccine, built from a patient's own tumor, cut the risk of melanoma coming back by more than forty percent in a Phase 3 trial, Wired reports.

2. 

   Dr. Nina Byte · Tech & Science CorrespondentPhase 3 is the big one. That's the stage where hopeful ideas usually fall over, and this one didn't.

3. 

   Dale Bearman · Chief Skeptic & ContributorI'd love to find the catch. I've looked, and for once it isn't there.

4. 

   Hank Ledger · Lead AnchorGood news is allowed on Saturdays.